The allotment status for the ₹939.70 crore Molbio Diagnostics IPO is likely to be finalised today, August 13, 2026. Investors can check their IPO allotment status on the official websites of the NSE, BSE, and the IPO registrar, KFin Technologies Limited.

Following the completion of the allotment process, the shares are tentatively scheduled to be listed on the NSE and BSE on August 17, 2026.

Procedure to Check Molbio Diagnostics IPO Allotment Status Online on NSE

Visit the NSE’s IPO allotment verification status page here.
Select “Equity & SME IPO Bid Details”.
In Select Symbol, choose “MOLBIO”.
Enter your PAN No. and Application No.
Click “Submit”.

Procedure to Check Molbio Diagnostics IPO Allotment Status Online on BSE

Click here to visit the application status page.
Under Issue Type, select “Equity”.
In Issue Name, select “Molbio Diagnostics Limited”.
Enter your “Application No. or PAN No.”
Enter the given Captcha correctly.
Click “Submit”.

Procedure to Check Molbio Diagnostics IPO Allotment Status on KFin Technologies Limited (Registrar to the Issue)

Visit the KFin Technologies’ IPO allotment status page here.
In Select IPO, select “MOLBIO DIAGNOSTICS LIMITED”.
Enter any one of the following details.

App. No.
Demat Account
PAN

Click “Submit”.

Molbio Diagnostics IPO - Issue Details

Issue Type: Book Built Issue (Fresh Issue + OFS)
Total Issue Size: Up to ₹939.70 crore
Fresh Issue: Up to ₹200.00 crore
Offer for Sale (OFS): Up to ₹739.70 crore
Face Value: ₹1 per equity share
Price Band: ₹768 to ₹807
Lot Size: 18 shares
Minimum Investment Amount (Retail Investor): ₹14,526 (18 shares at the upper price)
Listing: BSE, NSE
Book Running Lead Managers: Kotak Mahindra Capital Company Limited, IIFL Capital Services Limited, Jefferies India Private Limited and Motilal Oswal Investment Advisors Limited
Registrar: KFin Technologies Limited

Molbio Diagnostics IPO Overall Subscription Status

[August 12, 2026, 7:00 PM]

Category	Subscription (x)
Qualified Institutional Buyers (QIBs)	186.39x
Non-Institutional Investors (NIIs)	49.80x
Retail Individual Investors (RIIs)	12.96X
Total	70.26x

Utilisation of IPO Proceeds

The company intends to utilise the net proceeds from the fresh issue towards:

Funding capital expenditure for setting up infrastructure for a research and development facility and Centre of Excellence to be operated by the wholly owned subsidiary, Bigtec, along with office space for the company, its subsidiaries and associates.
Funding capital expenditure towards the purchase of certain plant, machinery and other equipment for Goa Unit I, Goa Unit II and Visakhapatnam Unit
General corporate purposes

About Molbio Diagnostics Limited

Founded in 2000, Molbio Diagnostics Limited develops point-of-care (POC) diagnostic solutions aimed at making molecular testing faster and more accessible for infectious and non-communicable diseases. Its flagship Truenat platform is a portable, battery-operated PCR system designed for use in resource-constrained settings and can deliver test results in about an hour. As of March 31, 2026, the company offered 43 assays covering 30 diseases, including tuberculosis (TB), COVID-19, HIV, hepatitis B and C, and HPV.

In addition to molecular diagnostics, Molbio has a presence in radiology, digital pathology and breast health screening through its subsidiaries and strategic partnerships. Its Truenat technology is patented in more than 100 countries. The company’s tuberculosis test is among the rapid molecular diagnostic tests recommended by the World Health Organization (WHO) for the initial detection of TB and rifampicin resistance.

Key Financial Highlights

Particulars	FY26 (in ₹ crore)	FY25 (in ₹ crore)	FY24 (in ₹ crore)
Revenue from operations	1,445.57	1,020.42	836.56
EBITDA	328.24	256.64	185.09
Profit After Tax (PAT)	164.14	138.58	83.54